🧬New Report 🧬
How has China prioritized collecting biological data, and what are the #medicalAI and #bioeconomy implications?
@VikramVenkatram, @clschuerger, and Katherine Quinn explore China’s biodata collection efforts. Read more here ⬇️ https://t.co/fOGA8gpvgU
🧬New Report 🧬
How has China prioritized collecting biological data, and what are the #medicalAI and #bioeconomy implications?
@VikramVenkatram, @clschuerger, and Katherine Quinn explore China’s biodata collection efforts. Read more here ⬇️ https://t.co/fOGA8gpvgU
Some of my last work from CSET is in print! Great working with @steph_batalis, @ggronvall, and Matt E. Walsh on the opportunities and challenges of the AI x Synthetic Bio convergence!
Sharing my new article in Applied Biosafety with Stephanie Batalis, Caroline Schuerger @clschuerger, and Matt E. Walsh on "Safeguarding Mail-Order DNA Synthesis in the Age of Artificial Intelligence."
https://t.co/4nYDUX3asI
Sharing my new article in Applied Biosafety with Stephanie Batalis, Caroline Schuerger @clschuerger, and Matt E. Walsh on "Safeguarding Mail-Order DNA Synthesis in the Age of Artificial Intelligence."
https://t.co/4nYDUX3asI
Much is misunderstood about gain-of-function research, and without taking a nuanced look at the issue, one-size-fits-all restrictions will do more harm than good, argue CSET's @steph_batalis + @clschuerger via @CFR_org's @ThinkGlobalHlth. Read more here ⬇️ https://t.co/K3G7PFKrJk
The main takeaway? Two things can be true at once: GOF/LOF research can be important for science and medicine while a subset can also be risky if conducted improperly. Differentiating between the two will require nuanced and careful policy.
Proud of all the work that went into this report, and glad it’s finding its way to a wider audience! This is just the tip of the iceberg - but it’s important to know what kind of research is happening on a large scale.
Why do researchers make pathogens more infectious? In our new report, we find that gain- and loss-of-function #research is widely used to develop new #vaccines or study pathogens that cause a high #GlobalHealth burden, like flu viruses. Read more: https://t.co/5GZjmDIZCr
Important perspective from Hopkins' Matt E. Walsh: "large language model-based chatbots and bio-design tools influence the biosecurity landscape in vastly different ways. Their governance, therefore, should be considered and developed independently."
https://t.co/cVrGPSh8S8
Our latest report adds additional insight into the gain-of-function discussion: we used machine learning to map and characterize approximately 7,000 scientific publications that use gain-or loss-of-function and discusses the regulatory opportunities and challenges
✨New Policy Brief✨
When it comes to regulating ‘risky’ gain of function research, one size does not fit all. Check out our new report describing the scale of this research + details on the range of methodologies, pathogens + public health applications. https://t.co/5GZjmDIZCr
Gain-of-function research: what is it? How and why do researchers do it? What does the research landscape look like?
So proud to be part of this report where we answer these questions and more using ~7,000 examples of gain- or loss-of-function research!
Drug discovery💊, unraveling the mystery of genetics🧬, and redefining precision medicine🎯are ALL being helped by the newly unleashed 💥power💥of #AI. Dive in @steph_batalis, @clschuerger, and @VikramVenkatram's summary to learn more!🔍🚀
https://t.co/JFtPtJSJe1
I signed my name in support of the bipartisan #DiseaseX Act of 2023 because the US needs sustained federal funding to prepare for unknown threats. Glad to see this legislature moving forward!
As we consider the future of LLMs in bio and medicine, the (very real!) discussion of risk needs to be balanced with the ways that LLMs already power health applications.
Check out my newest blog post below with @clschuerger and @VikramVenkatram!⬇️